Vaccines

Vaxcyte is arming itself with $1 billion in fresh capital to challenge Pfizer and Merck, leveraging a dual-tranche financing strategy to scale manufacturing.

Walgreens is blending clinical care with retail perks for its Oct. 6 Seniors Day, aiming to boost low vaccination rates while navigating operational hurdles.

Invivyd's VYD2311 beats mRNA vaccines on tolerability and boosts immunity, but regulatory and economic hurdles loom large for the novel therapy.

Ontario’s decision to fund a targeted adult pneumococcal vaccine offers a vital shield for seniors while easing the severe strain on our hospital systems.

As rabies breaches marine ecosystems and surges in Quebec, new biosecurity tech and cross-border collaborations are redefining wildlife disease containment.

A new study reveals an mRNA flu vaccine sustains immune responses for months, a breakthrough that could lead to multi-season protection and end the annual flu shot.

CSL Seqirus's new flu shot combines three proven technologies. A landmark Lancet study validates its strategic R&D investment in the senior healthcare market.

With its new COVID vaccine approved, Novavax is leveraging global partners like Sanofi to earn royalties, proving an asset-light model can rival industry giants.

As a deadly Bundibugyo ebolavirus outbreak grips the DRC, a $16.5M CEPI investment in Egypt's Minapharm marks a pivotal shift toward African health sovereignty.

A new trial for refractory melanoma relies on a breakthrough manufacturing platform from NTx Bio. This is how automation is making personalized vaccines a reality.

As Evaxion prepares its Q2 update, investors watch to see if its AI-Immunology™ platform can deliver the financial and clinical results for long-term value.

A biotech startup's nomination for a top award validates its unique platform, which uses a patient's own cells to fight cancer and prepare for future pandemics.

Stand Up To Cancer funds a bold new strategy against pancreatic cancer, pairing an mRNA vaccine with cellular therapy to finally target the elusive KRAS gene.

European approval for Bavarian Nordic's pediatric mpox vaccine is a critical health breakthrough and a masterclass in strategic market positioning.

Medgene's new vaccine offers a first line of defense against a deadly, tick-borne parasite ravaging US cattle, highlighting a new era in rapid-response animal health tech.

Arcturus Therapeutics heads to the Canaccord Growth Conference to spotlight its advanced mRNA platform, shifting focus from COVID vaccines to rare diseases.

Fresh off a massive Moderna settlement, Arbutus Biopharma expands its patent war against Pfizer and plans a $230M shareholder return, a bold strategic move.

Delonix Bioworks is running parallel trials in China and Australia for its MenB vaccine, a strategic gambit that could disrupt a billion-dollar market.

Immunomic Therapeutics begins human trials for ITI-9001, an saRNA vaccine aiming to rewrite the immune response to Japanese cedar pollen allergy.

Interim data shows AC Immune's Alzheimer's candidate is safe, but a pivot to boost its power reveals a high-stakes bet on efficacy over speed.